Related Experiment Video
Updated: Jul 5, 2026
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
Fulminant extraneural metastases in MYC-amplified Group 3 medulloblastoma: a pediatric case report
Lian Chen1, Shaoqun Li1, Lichao Wang1
1Department of Oncology, Guangdong Sanjiu Brain Hospital, No. 578, Shatai South Road, Baiyun District, Guangzhou, 510510, Guangdong Province, China.
Abstract:
Medulloblastoma (MB) with MYC amplification is associated with aggressive clinical behavior and a high risk of metastatic dissemination. Extraneural metastasis (ENM), although rare in the modern treatment era, remains a devastating manifestation linked to poor survival. We report a pediatric case of MB with high-level MYC amplification and NanoString-based molecular subgrouping confirming Group 3 identity in a 9-year-old girl who developed rapidly progressive and widespread ENMs involving the bone marrow, liver, lymph nodes, and peritoneum shortly after craniospinal irradiation. Planned adjuvant chemotherapy could not be initiated because of persistent cytopenias associated with marrow infiltration during disease progression. Targeted next-generation sequencing identified somatic alterations in PTEN, ARID2, and ERCC6, as well as a heterozygous germline SLX4 variant of uncertain clinical significance. While these findings do not establish a causal role in tumor progression, they further illustrate the molecular complexity of high-risk MB. The clinical course observed in this patient is consistent with prior reports linking MYC amplification to aggressive metastatic behavior. This case underscores the challenges of managing molecularly high-risk MB and highlights the importance of comprehensive molecular characterization and timely systemic therapy.
Insights
Medulloblastoma with MYC amplification, a high-risk brain tumor, can spread aggressively to extraneural sites. This case highlights the challenges in managing such aggressive pediatric cases and the need for molecular profiling.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Molecular Pathology
Background:
- Medulloblastoma (MB) with MYC amplification is linked to aggressive behavior and metastasis.
- Extraneural metastasis (ENM) in MB, though rare, portends a poor prognosis.
- Group 3 MB is associated with the highest risk of metastatic dissemination.
Purpose of the Study:
- To report a pediatric case of Group 3 MB with MYC amplification and extensive ENM.
- To illustrate the molecular complexity and clinical challenges in managing high-risk MB.
- To emphasize the importance of molecular characterization and timely systemic therapy.
Main Methods:
- Case report of a 9-year-old girl with medulloblastoma.
- NanoString-based molecular subgrouping confirmed Group 3 MB.
- Targeted next-generation sequencing identified somatic and germline alterations.
Main Results:
- The patient developed rapidly progressive, widespread ENMs (bone marrow, liver, lymph nodes, peritoneum).
- Chemotherapy was delayed due to cytopenias from marrow infiltration.
- Somatic alterations in PTEN, ARID2, ERCC6, and a germline SLX4 variant were identified.
Conclusions:
- The clinical course aligns with MYC amplification's association with aggressive metastatic behavior in MB.
- This case underscores the difficulties in treating molecularly high-risk medulloblastoma.
- Comprehensive molecular characterization and prompt systemic treatment are crucial for managing aggressive MB.
